The Motley Fool··James HalleyTwo Biotech Darlings Poised for Acquisition: Abivax and Nektar Signal M&A Targets
Abivax and Nektar Therapeutics are positioned as acquisition targets with promising drug candidates and upcoming phase 3 trial data, attracting interest from major pharmaceutical companies.
AMGNABBVLLYAZNABVX+1acquisitionbiotech